secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K/A
Filed at:   2026-01-07T23:59:59+00:00
Accession:  0001193125-26-004896
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa appoints Mario Accardi CEO effective Jan 1, 2026; base salary $600K, target bonus 50%
--------------------------------------------------------------------------------

- Employment Agreement signed Jan 5, 2026; base salary $600,000 per year.
- Target annual incentive bonus set at 50% of base salary, first eligible in 2027.
- Termination without cause or for good reason (outside 1-yr post-sale): 12 months salary continuation.
- Termination within 1 year post-sale event: lump sum of 18 months salary plus 150% target bonus.
- Agreement supersedes prior Orexia Ltd employment contract from Jan 2019.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000119312526004896/0001193125-26-004896-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000119312526004896/d51805d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-004896

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer